Shilpa Medicare Limited has informed the Exchange about certified true copy of NCLT order
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The NCLT Bengaluru bench has approved the Scheme of Amalgamation of Shilpa Therapeutics Private Limited, a wholly owned subsidiary, into its holding company Shilpa Medicare Limited, with the appointed date set as 1st April 2025. The certified copy of the order (dated 27th February 2026) was received by the company on 16th March 2026, and the scheme will come into effect once this certified copy is filed with the Registrar of Companies. Since the transferor is a wholly owned subsidiary, no new shares will be issued to shareholders — the existing shares of the subsidiary held by Shilpa Medicare will simply stand cancelled. All employees of Shilpa Therapeutics will be absorbed into Shilpa Medicare on no less favourable terms, and the authorised share capital of the subsidiary will be clubbed with that of the holding company.
This is a pure internal restructuring with no impact on the share count, dividend, or voting rights of existing Shilpa Medicare shareholders, as no new shares are being issued. The merger consolidates a loss-making subsidiary into a profit-making parent, which may slightly affect future tax outflows but simplifies the group's corporate structure. Investors are unlikely to see any direct stock price reaction from this news.